SpeciCare helps doctors and pathologists preserve viable tumor tissue through cryopreservation, enabling today’s most advanced cancer testing options—including genomic profiling, ex-vivo drug sensitivity testing, immunotherapy biomarker analysis, organoid development, and clinical trial readiness—without adding unnecessary workflow burden to the clinical team.

Cancer care is advancing faster than ever. Precision medicine, biomarker-driven treatment, personalized vaccines, immunotherapy, and clinical trial matching are reshaping what is possible for patients. But one critical part of the care pathway has not kept pace: how biopsy tissue is preserved, managed, and discussed before the procedure. Many advanced testing options depend on the quality, viability, and availability of tumor tissue, yet patients are often unaware that preservation decisions made at the time of biopsy may affect what options remain available later. Biomarker testing is now a core part of precision cancer care, helping physicians select treatments based on the unique molecular characteristics of a patient’s cancer.

For physicians, this creates a new and important responsibility. Informed consent in modern cancer care should not stop at explaining the biopsy procedure itself. It should also include a meaningful conversation about what may happen to the tissue after it is collected, how preservation methods may affect future testing, and whether the patient wants to preserve viable tissue for advanced diagnostics, treatment selection, recurrence planning, or clinical trial eligibility. NCI precision medicine programs and clinical trials increasingly rely on tumor molecular profiling and immune characterization to guide treatment decisions and trial matching.